Identifying Patients With BCG-Unresponsive High-Risk NMIBC Suitable for Treatment With TAR-200
TAR-200 is being studied for carcinoma in situ with or without papillary disease since it addresses diffuse CIS that cannot be surgically removed, though future trials will expand to papillary disease as adjuvant therapy like BCG, with the goal of extending the disease-free period before potentially reintroducing therapy as needed.
Recent Videos
Related Content
